PET with 18 F-FDG is the standard modality in nuclear medicine for imaging multiple myeloma (MM). However, viable MM as detected by MRI or PET with other metabolic tracers, including 11 C-methio-nine, may be missed—for example, because of low hexokinase 2 (HK2) expression of tumor cells. The aim of this study was to further investigate potential reasons for PET false negativity. Methods: A cohort of 15 mainly pretreated patients with relapsed or refractory biopsy-proven, serologically active MM who underwent both 18 F-FDG and 11 C-methionine PET/CT was retrospectively analyzed. Results: In 9 of the 15 patients, 18 F-FDG PET was negative in the presence of viable disease. In the remaining 6 patients, both 18 F-FDG and 11 C-methionine PET/CT revealed the same number of MM lesions. At immunohistochemistry, 18 F-FDG–negative myeloma did not exhibit significant differences in HK2 or glucose-6-phosphatase expression from 18 F-FDG–positive disease (P 5 0.57 and P 5 0.44, respectively). Conclusion: Beyond HK2 expression, 18 F-FDG negativity in (mainly pretreated) MM patients seems to be associated with additional causes not yet known.
Hexokinase-2 Expression in MET-positive FDG-negative Multiple Myeloma / S. Kircher, A. Stolzenburg, K. Kortüm, M. Kircher, M.C. DA VIA', S. Samnick, A. Buck, H. Einsele, A. Rosenwald, C. Lapa. - In: THE JOURNAL OF NUCLEAR MEDICINE. - ISSN 0161-5505. - 60:3(2018), pp. 348-352. [10.2967/jnumed.118.217539]
Hexokinase-2 Expression in MET-positive FDG-negative Multiple Myeloma
M.C. DA VIA';
2018
Abstract
PET with 18 F-FDG is the standard modality in nuclear medicine for imaging multiple myeloma (MM). However, viable MM as detected by MRI or PET with other metabolic tracers, including 11 C-methio-nine, may be missed—for example, because of low hexokinase 2 (HK2) expression of tumor cells. The aim of this study was to further investigate potential reasons for PET false negativity. Methods: A cohort of 15 mainly pretreated patients with relapsed or refractory biopsy-proven, serologically active MM who underwent both 18 F-FDG and 11 C-methionine PET/CT was retrospectively analyzed. Results: In 9 of the 15 patients, 18 F-FDG PET was negative in the presence of viable disease. In the remaining 6 patients, both 18 F-FDG and 11 C-methionine PET/CT revealed the same number of MM lesions. At immunohistochemistry, 18 F-FDG–negative myeloma did not exhibit significant differences in HK2 or glucose-6-phosphatase expression from 18 F-FDG–positive disease (P 5 0.57 and P 5 0.44, respectively). Conclusion: Beyond HK2 expression, 18 F-FDG negativity in (mainly pretreated) MM patients seems to be associated with additional causes not yet known.File | Dimensione | Formato | |
---|---|---|---|
348.full.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
570.88 kB
Formato
Adobe PDF
|
570.88 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.